Background: The clinical and angiographic outcome in humans after deployment of stents coated with paclitaxel into de-novo coronary artery lesions and in-stent restenoses was significantly superior to bare stents of same design. Coroflex짰 Please stent was coated with same drug (paclitaxel with a dose of 1 關g per mm2 of stent surface) as well as TAXUSTM LibertéTM stent but had different stent property and polymer. There are limited data to compare the clinical efficacy and safety between two paclitaxel-eluting stents. Methods: This study was aimed to investigate the comparison of 6 month clinical outcomes between Coroflex짰 Please stent and TAXUSTM LibertéTM stent. From January 2007 to February 2009, a cohort study of 235 patients has been implanted with paclitaxel eluting stents at our hospital. Among those, 111 patients were implanted with Coroflex짰 Please stents and 124 patients were done with TAXUSTM LibertéTM stents. Primary end point was major adverse cardiovascular event (MACE) at 6 month. MACE was a composite of cardiac death (CD), myocardial infarction (MI) and target lesion revascularization (TLR). Also stent thromboses (ST) by ARC definition were evaluated. Results: All patients were completed follow-up more than six months. Baseline demographic and procedural characteristics were similar between Coroflex짰 Please stent- and TAXUSTM LibertéTM stent-group. MACE at 6 month were 8.1% ( 2 CD, 3 MI, 4 TLR) in Coroflex짰 Please stent-group and 3.2% (1 CD, 1 MI, 2 TLR,) in TAXUSTM LibertéTM stent-group(p=0.102). The stent thrombosis (ST) was 1.8 % in Coroflex짰 Please stent-group and none in TAXUSTM LibertéTM stent-group (p=0.133). Conclusion: Coroflex짰 Please stent did not differ from TAXUSTM LibertéTM stent in terms of major adverse cardiac events and stent thrombosis during midterm clinical follow-up. Even though it is figured out that Coroflex짰 Please stent are equivalent to TAXUSTM LibertéTM stent, a large scaled study with long-term clinical and angiographic follow-up will be required.